These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 35587448)

  • 41. Hypertrophic cardiomyopathy in neonates with congenital hyperinsulinism.
    Huang T; Kelly A; Becker SA; Cohen MS; Stanley CA
    Arch Dis Child Fetal Neonatal Ed; 2013 Jul; 98(4):F351-4. PubMed ID: 23377780
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A specialized team approach to diagnosis and medical versus surgical treatment of infants with congenital hyperinsulinism.
    Palladino AA; Stanley CA
    Semin Pediatr Surg; 2011 Feb; 20(1):32-7. PubMed ID: 21186002
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and safety of octreotide for the treatment of congenital hyperinsulinism: a prospective, open-label clinical trial and an observational study in Japan using a nationwide registry.
    Hosokawa Y; Kawakita R; Yokoya S; Ogata T; Ozono K; Arisaka O; Hasegawa Y; Kusuda S; Masue M; Nishibori H; Sairenchi T; Yorifuji T
    Endocr J; 2017 Sep; 64(9):867-880. PubMed ID: 28701683
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Congenital hyperinsulinism in newborn and infant].
    Giurgea I; Ribeiro MJ; Boddaert N; Touati G; Robert JJ; Saudubray JM; Jaubert F; Bellanné-Chantelot C; Brunelle F; Nihoul-Fékété C; de Lonlay P
    Arch Pediatr; 2005 Nov; 12(11):1628-35. PubMed ID: 16198094
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Slow-release lanreotide treatment in endocrine gastrointestinal tumors.
    Tomassetti P; Migliori M; Gullo L
    Am J Gastroenterol; 1998 Sep; 93(9):1468-71. PubMed ID: 9732927
    [TBL] [Abstract][Full Text] [Related]  

  • 46. One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel.
    Caron P; Bex M; Cullen DR; Feldt-Rasmussen U; Pico Alfonso AM; Pynka S; Racz K; Schopohl J; Tabarin A; Valimaki MJ;
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):734-40. PubMed ID: 15163338
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Perspective on the Genetics and Diagnosis of Congenital Hyperinsulinism Disorders.
    Stanley CA
    J Clin Endocrinol Metab; 2016 Mar; 101(3):815-26. PubMed ID: 26908106
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
    Caplin ME; Pavel M; Ćwikła JB; Phan AT; Raderer M; Sedláčková E; Cadiot G; Wolin EM; Capdevila J; Wall L; Rindi G; Langley A; Martinez S; Blumberg J; Ruszniewski P;
    N Engl J Med; 2014 Jul; 371(3):224-33. PubMed ID: 25014687
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.
    Gadelha MR; Bronstein MD; Brue T; Coculescu M; Fleseriu M; Guitelman M; Pronin V; Raverot G; Shimon I; Lievre KK; Fleck J; Aout M; Pedroncelli AM; Colao A;
    Lancet Diabetes Endocrinol; 2014 Nov; 2(11):875-84. PubMed ID: 25260838
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lanreotide for the treatment of acromegaly.
    Castinetti F; Saveanu A; Morange I; Brue T
    Adv Ther; 2009 Jun; 26(6):600-12. PubMed ID: 19533047
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pancreatic surgery in infants with Beckwith-Wiedemann syndrome and hyperinsulinism.
    Laje P; Palladino AA; Bhatti TR; States LJ; Stanley CA; Adzick NS
    J Pediatr Surg; 2013 Dec; 48(12):2511-6. PubMed ID: 24314195
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The difficult management of persistent, non-focal congenital hyperinsulinism: A retrospective review from a single, tertiary center.
    Rasmussen AG; Melikian M; Globa E; Detlefsen S; Rasmussen L; Petersen H; Brusgaard K; Rasmussen AH; Mortensen MB; Christesen HT
    Pediatr Diabetes; 2020 May; 21(3):441-455. PubMed ID: 31997554
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical presentation and management of children with diffuse and focal hyperinsulinism: a review of 223 cases.
    Lord K; Dzata E; Snider KE; Gallagher PR; De León DD
    J Clin Endocrinol Metab; 2013 Nov; 98(11):E1786-9. PubMed ID: 24057290
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Monotherapy with lanreotide depot for acromegaly: long-term clinical experience in a pituitary center.
    Sagvand BT; Khairi S; Haghshenas A; Swearingen B; Tritos NA; Miller KK; Klibanski A; Nachtigall LB
    Pituitary; 2016 Aug; 19(4):437-47. PubMed ID: 27155600
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hyperinsulinemic Hypoglycemia Diagnosed in Childhood Can Be Monogenic.
    Hopkins JJ; Childs AJ; Houghton JAL; Hewat TI; Atapattu N; Johnson MB; Patel KA; Laver TW; Flanagan SE
    J Clin Endocrinol Metab; 2023 Feb; 108(3):680-687. PubMed ID: 36239000
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-term medical treatment in congenital hyperinsulinism: a descriptive analysis in a large cohort of patients from different clinical centers.
    Welters A; Lerch C; Kummer S; Marquard J; Salgin B; Mayatepek E; Meissner T
    Orphanet J Rare Dis; 2015 Nov; 10():150. PubMed ID: 26608306
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A single-center open-label study to investigate the efficacy and safety of repeated subcutaneous injections of lanreotide Autogel in patients with acromegaly previously treated with octreotide.
    Kelly P; Maher KT; Chew SL; Monson JP; Grossman AB; Jenkins PJ
    Endocr Pract; 2010; 16(2):191-7. PubMed ID: 19833584
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Somatostatin in the emergency treatment of persistent hypoglycemias caused by hyperinsulinism (nesidioblastosis of the pancreas)].
    Wendel U; Kardorff C; Dorittke P; Bremer HJ
    Monatsschr Kinderheilkd; 1985 Aug; 133(8):527-31. PubMed ID: 2864633
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Novel dominant K
    Boodhansingh KE; Kandasamy B; Mitteer L; Givler S; De Leon DD; Shyng SL; Ganguly A; Stanley CA
    Am J Med Genet A; 2019 Nov; 179(11):2214-2227. PubMed ID: 31464105
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and safety of lanreotide in postoperative dumping syndrome: A Phase II randomised and placebo-controlled study.
    Wauters L; Arts J; Caenepeel P; Holvoet L; Tack J; Bisschops R; Vanuytsel T
    United European Gastroenterol J; 2019 Oct; 7(8):1064-1072. PubMed ID: 31662863
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.